摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-异丁基-1H-吡唑 | 98816-40-1

中文名称
3-异丁基-1H-吡唑
中文别名
——
英文名称
3-isobutyl-1(2)H-pyrazole
英文别名
3-Isobutyl-1(2)H-pyrazol;3-isobutyl-1H-pyrazole;5-(2-methylpropyl)-1H-pyrazole
3-异丁基-1H-吡唑化学式
CAS
98816-40-1
化学式
C7H12N2
mdl
——
分子量
124.186
InChiKey
KLQAJWMVWOATSI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    28.7
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

点击查看最新优质反应信息

文献信息

  • PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE
    申请人:Nocion Therapeutics, Inc.
    公开号:US20210128589A1
    公开(公告)日:2021-05-06
    The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
    本发明提供了式(I)的化合物,或其药用可接受的盐: 本发明的化合物、组合物、方法和试剂盒可用于治疗疼痛、瘙痒和神经性炎症。
  • DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF
    申请人:Samumed, LLC
    公开号:US20190127370A1
    公开(公告)日:2019-05-02
    Diazanaphthalene compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a diazanaphthalene compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.
    本公开涉及使用二氮化合物或其类似物治疗通过激活Wnt途径信号传导特征的疾病的方法。更具体地,本公开涉及在治疗由Wnt途径信号传导激活所特征化的疾病(例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病、炎症、自身免疫疾病和骨关节炎)中使用二氮化合物或其类似物,以及调节由Wnt途径信号传导介导的细胞事件,以及与DYRK1A过表达相关的神经病症/紊乱/疾病。
  • 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF
    申请人:Samumed, LLC
    公开号:US20190119263A1
    公开(公告)日:2019-04-25
    Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.
    揭示了用于治疗各种疾病和病理的异喹啉化合物。更具体地,本公开涉及使用异喹啉化合物或其类似物,治疗由Wnt途径信号激活所特征化的疾病(例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病、炎症、自身免疫疾病和骨关节炎),以及通过Wnt途径信号介导的细胞事件的调节,以及与DYRK1A过表达相关的神经状况/疾病/疾病。
  • Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
    申请人:——
    公开号:US20040110785A1
    公开(公告)日:2004-06-10
    This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    这项发明提供了具有药物和生物影响特性的化合物,它们的药物组合物和使用方法。具体而言,该发明涉及吡啶咪唑酮乙酰基哌嗪生物。这些化合物具有独特的抗病毒活性,无论是单独使用还是与其他抗病毒药物、抗感染剂、免疫调节剂或HIV进入抑制剂结合使用。更具体地,本发明涉及治疗HIV和艾滋病。
  • KINASE INHIBITORS
    申请人:PRINCIPIA BIOPHARMA, INC.
    公开号:US20140323464A1
    公开(公告)日:2014-10-30
    Provided herein are kinase inhibiting compounds and methods of using the same.
    提供的是激酶抑制化合物及其使用方法。
查看更多